Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome

E-ISSN： 2212-3938|5|2|133-139

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.5, Iss.2, 2010-05, pp. : 133-139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dyslipidemia in the metabolic syndrome

By Chan Dick Watts Gerald

The Journal of Drug Evaluation, Vol. 2, Iss. 1, 2004-01 ,pp. : 3-34

Taylor & Francis Ltd

Access to resources Recommend Favorite

Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome

Current Pharmaceutical Design, Vol. 15, Iss. 29, 2009-10 ,pp. : 3446-3462

Bentham Science Publishers

Access to resources Recommend Favorite

Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 9, 2011-09 ,pp. : 1463-1480

Bentham Science Publishers

Access to resources Recommend Favorite

Management of Dyslipidemia in the Metabolic Syndrome: Recommendations of the Spanish HDL-Forum

By Ascaso Juan

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 1, 2007-01 ,pp. : 39-58

Adis International

Access to resources Recommend Favorite

Progranulin, a New Adipokine at the Crossroads of Metabolic Syndrome, Diabetes, Dyslipidemia and Hypertension

Current Pharmaceutical Design, Vol. 23, Iss. 10, 2017-05 ,pp. : 1533-1539

Bentham Science Publishers

Access to resources Recommend Favorite